AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners

  • CytomX Therapeutics Inc CTMX will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc ABBV decided not to advance the drug into additional studies
  • CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement.
  • AbbVie paid $30 million upfront in 2016 to ink the deal and another $15 million in milestones in 2017 for the start of toxicology studies.
  • Related: CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker.
  • Updated Phase 2 data for CX-2029, released in January, suggested CX-2029 spurred a 21% objective response rate (ORR) among a group of heavily pre-treated patients with squamous esophageal cancer. The ORR was 10% in squamous non-small cell lung cancer.
  • The adverse event profile was consistent with what was seen in Phase 1, with anemia being the most common side effect — experienced by 82.6% of patients in the trial.
  • CytomX restructured its business in July to prioritize internal investments in its emerging pre-clinical and early clinical pipeline and laid off 40% of its workforce
  • In 2022, the company generated revenue of $53.2 million compared to $37.3 million a year ago, driven by higher estimated percentages of completion for R&D programs in the company's collaborations with AbbVie, Astellas Pharma Inc ALPMF and Bristol Myers Squibb & Co BMY.
  • Cash, cash equivalents, and investments of $194 million exclude the $35 million cash payment received under the Moderna agreement in Q1 2023.
  • Price Action: CTMX shares are down 15.10% at $1.52 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsPenny StocksGuidanceHealth CareContractsMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!